Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Cancer. 2020 Dec 9;127(7):1057–1067. doi: 10.1002/cncr.33335

Table 3.

Comparison of hospitalization and mortality between racial groups.

Characteristic Hospitalization Mortality
Black Non-Black P-value Black Non-Black P-value
Overall – N (%) 48/67 (71.6) 58/126 (46.0) .001 14/67 (20.9) 20/126 (15.9) .50
Ethnicity – N (%)
 Hispanic 2/4 (50.0) 16/35 (45.7) 1.0 2/4 (50.0) 6/35 (17.1) .18
Age – N (%)
 <65 years 22/32 (68.8) 18/62 (29.0) <.001 6/32 (18.8) 5/62 (8.1) .23
 ≥65 years 26/35 (74.3) 40/64 (62.5) .33 8/35 (22.9) 15/64 (23.4) 1.0
BMI – N (%)
 Normal 11/15 (73.3) 15/34 (44.1) .07 5/15 (33.3) 8/34 (23.5) .71
 Overweight 5/11 (45.5) 15/35 (42.9) 1.0 1/11 (9.1) 3/35 (8.6) 1.0
 Obese 32/40 (80.0) 27/54 (50.0) .006 8/40 (20.0) 8/54 (14.8) .70
Smoking status – N (%)
 Former/current smoker 15/18 (83.3) 17/31 (54.8) .06 6/18 (33.3) 9/31 (29.0) 1.0
 Never smoker 31/46 (67.4) 40/93 (43.0) .01 6/46 (13.0) 11/93 (11.8) 1.0
 Unknown 2/3 (66.7) 1/2 (50.0) 1.0 2/3 (66.7) 0/2 (0.0) .40
County of residence – N (%)
 New York 7/14 (50.0) 16/27 (59.3) .81 1/14 (7.1) 7/27 (25.9) .31
 Brooklyn 17/21 (81.0) 12/27 (44.4) .02 5/21 (23.8) 1/27 (3.7) .10
 Queens 0/1 (0.0) 5/16 (31.2) 1.0 0/1 (0.0) 2/16 (12.5) 1.0
 Bronx 13/17 (76.5) 11/23 (47.8) .10 7/17 (41.2) 4/23 (17.4) .19
 Other 3/4 (75.0) 12/27 (44.4) .33 0/4 (0.0) 5/27 (18.5) 1.0
 Unknown 8/10 (80.0) 2/6 (33.3) .12 1/10 (10.0) 1/6 (16.7) 1.0
Primary language English – N (%) 42/57 (73.7) 40/86 (46.5) .002 13/57 (22.8) 12/86 (14.0) .25
Current living situation – N (%)
 Alone 13/19 (68.4) 9/20 (45.0) .25 4/19 (21.1) 4/20 (20.0) 1.0
 Family 25/36 (69.4) 37/89 (41.6) .009 4/36 (11.1) 8/89 (9.0) .98
 Skilled nursing facility 2/2 (100.0) 4/5 (80.0) 1.0 1/2 (50.0) 3/5 (60.0) 1.0
 Unknown 8/10 (80.0) 8/12 (66.7) .65 5/10 (50.0) 5/12 (41.7) 1.0
Employed – N (%) 11/15 (73.3) 16/45 (35.6) .02 5/15 (33.3) 6/45 (13.3) .18
Worker in essential industry – N (%) 6/8 (75.0) 4/14 (28.6) .07 4/8 (50.0) 1/14 (7.1) .04
Insurance – N (%)
 Public 39/49 (79.6) 39/73 (53.4) .006 11/49 (22.4) 14/73 (19.2) .83
 Private 9/18 (50.0) 19/53 (35.8) .43 3/18 (16.7) 6/53 (11.3) .86
Performance status – N (%)
 <2 33/47 (70.2) 38/101 (37.6) <.001 9/47 (19.1) 11/101 (10.9) .27
 ≥2 11/13 (84.6) 12/14 (85.7) 1.0 4/13 (30.8) 6/14 (42.9) .80
Number of comorbidities ≥3 – N (%) 30/37 (81.1) 29/49 (59.2) .05 8/37 (21.6) 12/49 (24.5) .96
Comorbidity – N (%)
 Asthma 9/11 (81.8) 6/10 (60.0) .36 1/11 (9.1) 3/10 (30.0) .51
 COPD/emphysema 2/3 (66.7) 2/2 (100.0) 1.0 0/3 (0.0) 2/2 (100.0) .10
 Obstructive sleep apnea 4/4 (100.0) 6/8 (75.0) .52 1/4 (25.0) 3/8 (37.5) 1.0
 Pulmonary embolism 5/6 (83.3) 3/5 (60.0) .55 1/6 (16.7) 1/5 (20.0) 1.0
 Hypertension 37/50 (74.0) 37/65 (56.9) .09 12/50 (24.0) 13/65 (20.0) .77
 Coronary artery disease 7/7 (100.0) 3/6 (50.0) .07 3/7 (42.9) 1/6 (16.7) .56
 CKD/ESRD 9/11 (81.8) 9/10 (90.0) 1.0 2/11 (18.2) 5/10 (50.0) .28
 Diabetes mellitus 24/32 (75.0) 25/38 (65.8) .56 8/32 (25.0) 8/38 (21.1) .92
 Autoimmune disease 4/7 (57.1) 6/11 (54.5) 1.0 1/7 (14.3) 4/11 (36.4) .63
Cancer stage – N (%)
 I/II 20/26 (76.9) 19/48 (39.6) .005 5/26 (19.2) 8/48 (16.7) 1.0
 III/IV 25/38 (65.8) 26/62 (41.9) .03 9/38 (23.7) 10/62 (16.1) .50
 Unknown 3/3 (100.0) 13/16 (81.2) 1.0 0/3 (0.0) 2/16 (12.5) 1.0